PUMA BIOTECHNOLOGY INC (PBYI)

7 Stocks Under $15 Predicted to Boom in the Next 2 Years

Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Notable earnings after Thursday's close

Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

3 Strong Buy Stocks Under $5: January 2024

A strong buy rating carries weight which speculative investors may want to research in these strong buy stocks under $5.

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Third Quarter 2023 Financial Results

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

Puma Biotechnology Reports Second Quarter Financial Results

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Thursday morning!

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports First Quarter Financial Results

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology